ECKERT & ZIEGLER SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.2 EUR | -0.24% |
|
-3.49% | -19.61% |
| Sales 2024 * | 268M 285M | Sales 2025 * | 294M 314M | Capitalization | 691M 737M |
|---|---|---|---|---|---|
| Net income 2024 * | 31M 33.02M | Net income 2025 * | 34M 36.22M | EV / Sales 2024 * | 2.43 x |
| Net cash position 2024 * | 41.5M 44.21M | Net cash position 2025 * | 37.9M 40.37M | EV / Sales 2025 * | 2.22 x |
| P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
19.9
x | Employees | 1,075 |
| Yield 2024 * |
1.51% | Yield 2025 * |
1.51% | Free-Float | 66.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eckert & Ziegler SE
More recommendations
More press releases
| 1 day | -0.24% | ||
| 1 week | -3.49% | ||
| Current month | -11.42% | ||
| 1 month | -14.17% | ||
| 3 months | -20.80% | ||
| 6 months | +3.04% | ||
| Current year | -19.61% |
1 week
32.74
35.54
1 month
32.7440.44
Current year
32.7446.90
1 year
28.9250.05
3 years
28.92141.40
5 years
17.98141.40
10 years
4.15141.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 16-12-31 | |
Andreas Eckert
FOU | Founder | 55 | 96-12-31 |
Karolin Riehle
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edgar Löffler
BRD | Director/Board Member | 71 | 18-12-31 |
Andreas Eckert
FOU | Founder | 55 | 96-12-31 |
Frank Perschmann
BRD | Director/Board Member | 71 | 19-05-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.10% | 125 M€ | -.--% | ||
| 0.43% | 17 M€ | -.--% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 33.2 | -0.24% | 64,334 |
| 24-04-18 | 33.28 | -1.19% | 35,191 |
| 24-04-17 | 33.68 | -1.06% | 34,494 |
| 24-04-16 | 34.04 | -3.24% | 31,933 |
| 24-04-15 | 35.18 | +2.27% | 50,244 |
Delayed Quote Xetra, April 19, 2024 at 11:35 am EDT
More quotes
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Sector
Office Equipment
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
33.2
EUR
Average target price
60
EUR
Spread / Average Target
+80.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.61% | 738M | |
| +4.11% | 7.83B | |
| -13.04% | 2.72B | |
| +3.17% | 2.11B | |
| -30.67% | 1.06B | |
| -11.35% | 774M | |
| -33.88% | 650M | |
| -57.88% | 667M | |
| -31.34% | 612M | |
| -38.03% | 555M |
- Stock Market
- Equities
- EUZ Stock
